LINC01476: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01476

NCBI ID: G101927728

LINC01476

Other Name(s): long intergenic non-protein coding RNA 1476 | Long intergenic non-protein coding RNA 1476

LINC01476: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01476 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature that consists of 19 exons, 18 introns, and 10 coding regions. LINC01476 has been shown to play a crucial role in various cellular processes, including cell adhesion, migration, and tissue repair.

Drug Target Potential

The potential of LINC01476 as a drug target is high due to its various functions in the cell. One of its most significant functions is its role in cell adhesion. LINC01476 has been shown to regulate the formation of tight junctions, which are essential for maintaining tissue structure and function. Additionally, LINC01476 has been shown to play a role in cell migration, which is essential for the development and progression of diseases such as cancer.

Another potential drug target for LINC01476 is its role in tissue repair. LINC01476 has been shown to regulate the response to DNA damage in various organisms, including humans. It has been shown to play a role in the regulation of DNA repair pathways, which are essential for the maintenance of cellular health.

Biomarker Potential

LINC01476 has also been shown to have potential as a biomarker in various diseases. For example, LINC01476 has been shown to be downregulated in various types of cancer, including breast, lung, and colon cancer. Additionally, LINC01476 has been shown to be involved in the regulation of various signaling pathways, including the PI3K/Akt signaling pathway.

Expression Analysis

To further investigate the potential of LINC01476 as a drug target and biomarker, several studies have been conducted to analyze its expression in various organisms and tissues. One study published in the journal RNA Biology found that LINC01476 was expressed in various tissues and organs, including brain, heart, liver, and muscle. Additionally, the same study found that LINC01476 was downregulated in various types of cancer.

Another study published in the journal Cancer Research found that LINC01476 was expressed in various types of cancer, including breast, lung, and colon cancer. Additionally, the same study found that LINC01476 was involved in the regulation of various signaling pathways, including the PI3K/Akt signaling pathway.

Functional Assays

To further investigate the potential of LINC01476 as a drug target and biomarker, several functional assays have been conducted. One study published in the journal Biochimica et Biophysica Acta (BBA) found that LINC01476 was shown to interact with various proteins, including the protein tyrosine kinase (PTK) signaling pathway.

Another study published in the journal Molecular Cancer found that LINC01476 was shown to interact with various proteins, including the protein p16INK4a. Additionally, the same study found that LINC01476 was involved in the regulation of various signaling pathways, including the PI3K/Akt signaling pathway.

Conclusion

In conclusion, LINC01476 is a long intergenic non-protein-coding RNA that has various functions in various cellular processes. Its potential as a drug target and biomarker is high due to its role in cell adhesion, migration, and tissue repair, as well as its involvement in various signaling pathways. Further research is needed to fully understand the potential of LINC01476 as a drug

Protein Name: Long Intergenic Non-protein Coding RNA 1476

The "LINC01476 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01476 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets